Psyence Group (TSE:PSYG) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Psyence Group’s associate company, Psyence Biomed, is making significant strides in the field of mental health treatment with nature-derived psilocybin. They have initiated a Phase IIb study for Adjustment Disorder in Palliative Care, expanded their pipeline to include treatments for Substance Use Disorders, and announced a potential acquisition that could lead to the development of synthetic psilocybin-based therapies. These developments, coupled with secured funding, poise Psyence Biomed for pivotal Phase III trials and commercialization.
For further insights into TSE:PSYG stock, check out TipRanks’ Stock Analysis page.